Jacqueline M Kraveka

Title
InstitutionMedical University of South Carolina
DepartmentPediatric Hematology/Oncology
AddressP.O. Box MSC 561
CR 306
Rutledge Tower Building - 135 Rutledge Ave.
Phone843-792-2957
Fax843-792-8912
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Kraveka is graduate of Columbia University. She obtained her medical degree from Nova Southeastern University in North Miami Beach, Florida, in 1994. She completed her pediatric residency at Miami Children’s Hospital in 1997 and her fellowship in Pediatric Hematology-Oncology at the Medical University of South Carolina in 2000. Dr. Kraveka is actively involved in clinical pediatric research in the Children’s Oncology Group, where she is a member of the Non-Hodgkin’s Lymphoma and Neuroblastoma Committees. As the institutional COG Principal Investigator, she is responsible for the conduct of over 50 COG Phase II and Phase III trials at MUSC. Dr. Kraveka has served as the study chair for the COG Study, ANHL0131: A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma with Standard APO (Doxorubicin, Prednisone, Vincristine) versus Consolidation with a Regimen. Dr. Kraveka also serves as the institutional Principal Investigator for the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC). NMTRC consists of a group of closely collaborating investigators who are linked with laboratory programs to develop novel therapies. Those treatments with promising results will then be considered for more extensive national testing. In addition to clinical research, she is also very involved in translational and bench research and has the only research laboratory in South Carolina dedicated to pediatric cancer. Her current research focuses on sphingolipid mediated signal transduction in pediatric cancers, the function and regulation of the enzyme dihydroceramide desaturase in human cancer and the regulation of MYCN oncogene by sphingolipids. The long-term goal of her research is to develop novel therapeutic strategies for the treatment of childhood cancers, particularly neuroblastoma and pediatric sarcomas.
    Collapse keywords
    Cancer/Leukemia, Cancer/Other, Central Nervous System, Adolescents, Bone, Cancer, Cancer/Brain, Pediatrics

    Collapse ORNG Applications 
    Collapse studies/trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lewis EC, Kraveka JM, Ferguson W, Eslin D, Brown VI, Bergendahl G, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Zage P, Rawwas J, Rich M, Lorenzi E, Broglio K, Berry D, Saulnier Sholler GL. A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma. Int J Cancer. 2020 12 01; 147(11):3152-3159. PMID: 32391579.
      Citations:    
    2. Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 08 27; 322(8):746-755. PMID: 31454045.
      Citations:    
    3. Bai A, Bielawska A, Rahmaniyan M, Kraveka JM, Bielawski J, Hannun YA. Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites. Bioorg Med Chem. 2018 12 15; 26(23-24):6067-6075. PMID: 30448190.
      Citations:    
    4. Sholler GLS, Ferguson W, Bergendahl G, Bond JP, Neville K, Eslin D, Brown V, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Parikh NS, Eshun F, Zage P, Rawwas J, Sencer S, Pankiewicz D, Quinn M, Rich M, Junewick J, Kraveka JM. Maintenance DFMO Increases Survival in High Risk Neuroblastoma. Sci Rep. 2018 09 27; 8(1):14445. PMID: 30262852.
      Citations:    
    5. Swift CC, Eklund MJ, Kraveka JM, Alazraki AL. Updates in Diagnosis, Management, and Treatment of Neuroblastoma. Radiographics. 2018 Mar-Apr; 38(2):566-580. PMID: 29528815.
      Citations:    
    6. Boppana NB, Kraveka JM, Rahmaniyan M, Li LI, Bielawska A, Bielawski J, Pierce JS, Delor JS, Zhang K, Korbelik M, Separovic D. Fumonisin B1 Inhibits Endoplasmic Reticulum Stress Associated-apoptosis After FoscanPDT Combined with C6-Pyridinium Ceramide or Fenretinide. Anticancer Res. 2017 02; 37(2):455-463. PMID: 28179290.
      Citations:    
    7. Venant H, Rahmaniyan M, Jones EE, Lu P, Lilly MB, Garrett-Mayer E, Drake RR, Kraveka JM, Smith CD, Voelkel-Johnson C. The Sphingosine Kinase 2 Inhibitor ABC294640 Reduces the Growth of Prostate Cancer Cells and Results in Accumulation of Dihydroceramides In Vitro and In Vivo. . 2015 Dec; 14(12):2744-52. PMID: 26494858.
      Citations:    
    8. Mitchell D, Bergendahl G, Ferguson W, Roberts W, Higgins T, Ashikaga T, DeSarno M, Kaplan J, Kraveka J, Eslin D, Werff AV, Hanna GK, Sholler GL. A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. Pediatr Blood Cancer. 2016 Jan; 63(1):39-46. PMID: 26235333.
      Citations:    
    9. Saulnier Sholler GL, Gerner EW, Bergendahl G, MacArthur RB, VanderWerff A, Ashikaga T, Bond JP, Ferguson W, Roberts W, Wada RK, Eslin D, Kraveka JM, Kaplan J, Mitchell D, Parikh NS, Neville K, Sender L, Higgins T, Kawakita M, Hiramatsu K, Moriya SS, Bachmann AS. A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma. PLoS One. 2015; 10(5):e0127246. PMID: 26018967.
      Citations:    
    10. Saulnier Sholler GL, Bond JP, Bergendahl G, Dutta A, Dragon J, Neville K, Ferguson W, Roberts W, Eslin D, Kraveka J, Kaplan J, Mitchell D, Parikh N, Merchant M, Ashikaga T, Hanna G, Lescault PJ, Siniard A, Corneveaux J, Huentelman M, Trent J. Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. Cancer Med. 2015 Jun; 4(6):871-86. PMID: 25720842.
      Citations:    
    11. Alexander S, Kraveka JM, Weitzman S, Lowe E, Smith L, Lynch JC, Chang M, Kinney MC, Perkins SL, Laver J, Gross TG, Weinstein H. Advanced stage anaplastic large cell lymphoma in children and adolescents: results of ANHL0131, a randomized phase III trial of APO versus a modified regimen with vinblastine: a report from the children's oncology group. Pediatr Blood Cancer. 2014 Dec; 61(12):2236-42. PMID: 25156886.
      Citations:    
    12. Mattix B, Moore T, Uvarov O, Pollard S, O'Donnell L, Park K, Horne D, Dhulekar J, Reese L, Nguyen D, Kraveka J, Burg K, Alexis F. EFFECTS OF POLYMERIC NANOPARTICLE SURFACE PROPERTIES ON INTERACTION WITH BRAIN TUMOR ENVIRONMENT. Nano Life. 2013 Dec 17; 3(4):1343003. PMID: 25110523.
      Citations:    
    13. Separovic D, Breen P, Boppana NB, Van Buren E, Joseph N, Kraveka JM, Rahmaniyan M, Li L, Gudz TI, Bielawska A, Bai A, Bielawski J, Pierce JS, Korbelik M. Increased killing of SCCVII squamous cell carcinoma cells after the combination of Pc 4 photodynamic therapy and dasatinib is associated with enhanced caspase-3 activity and ceramide synthase 1 upregulation. Int J Oncol. 2013 Dec; 43(6):2064-72. PMID: 24126464.
      Citations:    
    14. Breen P, Joseph N, Thompson K, Kraveka JM, Gudz TI, Li L, Rahmaniyan M, Bielawski J, Pierce JS, VAN Buren E, Bhatti G, Separovic D. Dihydroceramide desaturase knockdown impacts sphingolipids and apoptosis after photodamage in human head and neck squamous carcinoma cells. Anticancer Res. 2013 Jan; 33(1):77-84. PMID: 23267130.
      Citations:    
    15. Smith L, Minter S, O'Brien P, Kraveka JM, Medina AM, Lazarchick J. Neuroblastoma in an adult: case presentation and literature review. Ann Clin Lab Sci. 2013; 43(1):81-4. PMID: 23462610.
      Citations:    
    16. Meyers-Needham M, Lewis JA, Gencer S, Sentelle RD, Saddoughi SA, Clarke CJ, Hannun YA, Norell H, da Palma TM, Nishimura M, Kraveka JM, Khavandgar Z, Murshed M, Cevik MO, Ogretmen B. Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction. . 2012 May; 11(5):1092-102. PMID: 22452947.
      Citations:    
    17. Spassieva SD, Rahmaniyan M, Bielawski J, Clarke CJ, Kraveka JM, Obeid LM. Cell density-dependent reduction of dihydroceramide desaturase activity in neuroblastoma cells. J Lipid Res. 2012 May; 53(5):918-928. PMID: 22377532.
      Citations:    
    18. Rahmaniyan M, Curley RW, Obeid LM, Hannun YA, Kraveka JM. Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide. J Biol Chem. 2011 Jul 15; 286(28):24754-64. PMID: 21543327.
      Citations:    
    19. Idkowiak-Baldys J, Apraiz A, Li L, Rahmaniyan M, Clarke CJ, Kraveka JM, Asumendi A, Hannun YA. Dihydroceramide desaturase activity is modulated by oxidative stress. Biochem J. 2010 Mar 29; 427(2):265-74. PMID: 20105137.
      Citations:    
    20. Jin J, Hou Q, Mullen TD, Zeidan YH, Bielawski J, Kraveka JM, Bielawska A, Obeid LM, Hannun YA, Hsu YT. Ceramide generated by sphingomyelin hydrolysis and the salvage pathway is involved in hypoxia/reoxygenation-induced Bax redistribution to mitochondria in NT-2 cells. J Biol Chem. 2008 Sep 26; 283(39):26509-17. PMID: 18676372.
      Citations:    
    21. Kraveka JM, Li L, Szulc ZM, Bielawski J, Ogretmen B, Hannun YA, Obeid LM, Bielawska A. Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells. J Biol Chem. 2007 Jun 08; 282(23):16718-28. PMID: 17283068.
      Citations:    
    22. Laver JH, Kraveka JM, Hutchison RE, Chang M, Kepner J, Schwenn M, Tarbell N, Desai S, Weitzman S, Weinstein HJ, Murphy SB. Advanced-stage large-cell lymphoma in children and adolescents: results of a randomized trial incorporating intermediate-dose methotrexate and high-dose cytarabine in the maintenance phase of the APO regimen: a Pediatric Oncology Group phase III trial. J Clin Oncol. 2005 Jan 20; 23(3):541-7. PMID: 15659500.
      Citations:    
    23. Sultan I, Kraveka JM, Lazarchick J. CD19 negative precursor B acute lymphoblastic leukemia presenting with hypercalcemia. Pediatr Blood Cancer. 2004 Jul; 43(1):66-9. PMID: 15170892.
      Citations:    
    24. Kraveka JM, Li L, Bielawski J, Obeid LM, Ogretmen B. Involvement of endogenous ceramide in the inhibition of telomerase activity and induction of morphologic differentiation in response to all-trans-retinoic acid in human neuroblastoma cells. Arch Biochem Biophys. 2003 Nov 15; 419(2):110-9. PMID: 14592454.
      Citations:    
    25. Luberto C, Kraveka JM, Hannun YA. Ceramide regulation of apoptosis versus differentiation: a walk on a fine line. Lessons from neurobiology. Neurochem Res. 2002 Aug; 27(7-8):609-17. PMID: 12374196.
      Citations:    
    Kraveka's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (169)
    Explore
    _
    Co-Authors (14)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _